Aptose to Present at Canaccord Genuity 2021 Horizons in Oncology Virtual Conference
Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS) will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference on April 15, 2021, from 3:00 to 3:55 PM EDT. CEO William G. Rice, Ph.D. will join a panel discussing opportunities in BPDCN and AML, moderated by John Newman, Ph.D.
The company focuses on developing personalized therapies for oncology, particularly hematology. Their pipeline includes luxeptinib, a mutation-agnostic FLT3/BTK inhibitor, and APTO-253, which targets the MYC oncogene.
- None.
- None.
SAN DIEGO and TORONTO, April 08, 2021 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. (Nasdaq: APTO; TSX: APS), a clinical-stage company developing highly differentiated therapeutics that target the underlying mechanisms of cancer, today announced that William G. Rice, Ph.D., Chairman, President and Chief Executive Officer, will participate in Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference:
Canaccord Genuity’s 2021 Horizons in Oncology Virtual Conference
| ||
| Date: | Thursday, April 15, 2021 | |
| Time: | 3:00 – 3:55 PM EDT | |
| Format: | Panel Moderated by John Newman, Ph.D., Managing Director, Biotechnology Analyst | |
| Conference Information: Link | ||
The Aptose management team also will be hosting 1x1 meetings during the event.
About Aptose
Aptose Biosciences is a clinical-stage biotechnology company committed to developing personalized therapies addressing unmet medical needs in oncology, with an initial focus on hematology. The Company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. The Company has two clinical-stage investigational products for hematologic malignancies: luxeptinib (CG-806), an oral, first-in-class mutation-agnostic FLT3/BTK kinase inhibitor, is in a Phase 1a/b trial in patients with relapsed or refractory B cell malignancies, including chronic lymphocytic leukemia (CLL), small lymphocytic lymphoma (SLL) and non-Hodgkin lymphoma (NHL), who have failed or are intolerant to standard therapies, and is in a separate Phase 1a/b trial in patients with relapsed or refractory acute myeloid leukemia (AML); APTO-253, the only clinical-stage agent that directly targets the MYC oncogene and suppresses its expression, is in a Phase 1a/b clinical trial for the treatment of patients with relapsed or refractory AML or high risk myelodysplastic syndrome (MDS).
For further information, please contact:
Aptose Biosciences Inc.
Susan Pietropaolo
Investor Relations
201-923-2049
spietropaolo@aptose.com
LifeSci Advisors, LLC
Dan Ferry, Managing Director
617-535-7746
Daniel@LifeSciAdvisors.com
FAQ
What is the date of the Canaccord Genuity 2021 Horizons in Oncology Virtual Conference for Aptose?
What time will Aptose's panel discussion happen at the conference?
Who is moderating the panel on opportunities in BPDCN and AML at the conference?
What are the main focuses of Aptose Biosciences in oncology?
What clinical-stage products are currently in Aptose's pipeline?
